Alex Fu - Search Results

Year	Number of Results
2003	1
2004	2
2005	1
2006	4
2007	9
2008	13
2009	13
2010	13
2011	6
2012	4
2013	4
2014	3
2015	8
2016	9
2017	6
2018	6
2019	5
2020	5
2021	1
2022	8
2023	7
2024	2

1

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.

Durie BGM, Kumar SK, Ammann EM, Fu AZ, Kaila S, Lam A, Usmani SZ, Facon T. Durie BGM, et al. Among authors: fu az. Adv Ther. 2024 May;41(5):1923-1937. doi: 10.1007/s12325-024-02807-y. Epub 2024 Mar 18. Adv Ther. 2024. PMID: 38494542 Free PMC article.

2

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.

Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F, Usmani SZ. Gordan LN, et al. Among authors: fu az. Clin Lymphoma Myeloma Leuk. 2024 Jan;24(1):55-63. doi: 10.1016/j.clml.2023.09.003. Epub 2023 Sep 14. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37838502 Free article.

3

Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.

Pesa J, Liu Z, Fu AZ, Campbell AK, Grucza R. Pesa J, et al. Among authors: fu az. Schizophr Res. 2023 Nov;261:170-177. doi: 10.1016/j.schres.2023.09.033. Epub 2023 Sep 29. Schizophr Res. 2023. PMID: 37778124

4

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States.

Fonseca R, Chinaeke EE, Gupta-Werner N, Fu AZ, Kaila S. Fonseca R, et al. Among authors: fu az. Mayo Clin Proc Innov Qual Outcomes. 2023 Sep 15;7(5):430-436. doi: 10.1016/j.mayocpiqo.2023.07.001. eCollection 2023 Oct. Mayo Clin Proc Innov Qual Outcomes. 2023. PMID: 37731678 Free PMC article.

5

Racial and Ethnic Disparities in Treatment Initiation Among Patients with Newly Diagnosed Psoriatic Arthritis: A Retrospective Medicaid Claims Database Study.

Patel AA, Ferrante SA, Lin I, Fu AZ, Campbell AK, Tieng A. Patel AA, et al. Among authors: fu az. Rheumatol Ther. 2023 Oct;10(5):1241-1253. doi: 10.1007/s40744-023-00580-y. Epub 2023 Jul 15. Rheumatol Ther. 2023. PMID: 37453020 Free PMC article.

6

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia.

Basu A, Patel C, Fu AZ, Brown B, Mavros P, Benson C. Basu A, et al. Among authors: fu az. J Manag Care Spec Pharm. 2023 Mar;29(3):293-302. doi: 10.18553/jmcp.2023.22191. Epub 2023 Jan 24. J Manag Care Spec Pharm. 2023. PMID: 36692909 Free PMC article. Clinical Trial.

7

Hypomorphic and dominant-negative impact of truncated SOX9 dysregulates Hedgehog-Wnt signaling, causing campomelia.

Au TYK, Yip RKH, Wynn SL, Tan TY, Fu A, Geng YH, Szeto IYY, Niu B, Yip KY, Cheung MCH, Lovell-Badge R, Cheah KSE. Au TYK, et al. Among authors: fu a. Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2208623119. doi: 10.1073/pnas.2208623119. Epub 2022 Dec 30. Proc Natl Acad Sci U S A. 2023. PMID: 36584300 Free PMC article.

8

Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.

Cai Q, Ding Z, Fu AZ, Patel AA. Cai Q, et al. Among authors: fu az. BMC Gastroenterol. 2022 Dec 29;22(1):545. doi: 10.1186/s12876-022-02560-y. BMC Gastroenterol. 2022. PMID: 36581802 Free PMC article.

9

Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients.

Ran T, Medhekar R, Fu AZ, Patel S, Kaila S. Ran T, et al. Among authors: fu az. Future Oncol. 2022 Nov;18(36):3983-3991. doi: 10.2217/fon-2022-0933. Epub 2022 Nov 15. Future Oncol. 2022. PMID: 36377712 Free article.

10

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.

Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Medhekar R, et al. Among authors: fu az. BMC Cancer. 2022 Aug 18;22(1):901. doi: 10.1186/s12885-022-09980-9. BMC Cancer. 2022. PMID: 35982416 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

109 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year